Clinical Outcomes of Metachronous Gastric Cancer after Endoscopic Resection for Early Gastric Cancer
1
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Background/Aims: Patients treated with endoscopic submucosal dissection (ESD) for early gastric cancer (EGC) are at risk of developing metachronous gastric cancer (MGC). The aim of this study was to evaluate the clinical outcomes of MGC after ESD for EGC between the re-ESD and surgery groups. Methods: In total, data from 1,510 patients who underwent ESD for EGC from January 2005 to May 2014 were retrospectively reviewed, and data from 112 patients with MGC were analyzed according to the type of treatment, namely, re-ESD and surgery. The clinicopathological factors affecting the subsequent treatment and outcomes of MGC were evaluated. Results: The median duration to the development of MGC was 47 months. In multivariate analysis, lower body mass index (BMI) (p=0.037) and multiplicity (p=0.014) of index cases were significantly associated with subsequent surgery for MGC. In cases of MGC, a diffuse or mixed-type Lauren classification (p=0.009), the depth of tumor mucosal invasion (p=0.001), and an upper stomach location (p=0.049) were associated with surgery. Overall survival was significantly shorter in the surgery group than in the re-ESD group after treatment for MGC (log-rank test, p=0.01). Conclusions: Lower BMI and multiplicity of index cancers were significantly associated with the surgical resection of MGC. Close follow-up is needed to minimize additional treatment for cases at high risk of advanced MGC after ESD for EGC.
Abstract
Background/Aims: Patients treated with endoscopic submucosal dissection (ESD) for early gastric cancer (EGC) are at risk of developing metachronous gastric cancer (MGC). The aim of this study was to evaluate the clinical outcomes of MGC after ESD for EGC between the re-ESD and surgery groups. Methods: In total, data from 1,510 patients who underwent ESD for EGC from January 2005 to May 2014 were retrospectively reviewed, and data from 112 patients with MGC were analyzed according to the type of treatment, namely, re-ESD and surgery. The clinicopathological factors affecting the subsequent treatment and outcomes of MGC were evaluated. Results: The median duration to the development of MGC was 47 months. In multivariate analysis, lower body mass index (BMI) (p=0.037) and multiplicity (p=0.014) of index cases were significantly associated with subsequent surgery for MGC. In cases of MGC, a diffuse or mixed-type Lauren classification (p=0.009), the depth of tumor mucosal invasion (p=0.001), and an upper stomach location (p=0.049) were associated with surgery. Overall survival was significantly shorter in the surgery group than in the re-ESD group after treatment for MGC (log-rank test, p=0.01). Conclusions: Lower BMI and multiplicity of index cancers were significantly associated with the surgical resection of MGC. Close follow-up is needed to minimize additional treatment for cases at high risk of advanced MGC after ESD for EGC.
참고문헌 (30)
- Ferlay J, "Cancer incidence and mortality worldwide : sources, methods and major patterns in GLOBOCAN 2012", Int J Cancer, 136, pp.E359~E386 (2015)
- Toshihiro Nishizawa, "Long-Term Outcomes of Using Endoscopic Submucosal Dissection to Treat Early Gastric Cancer", Gut and Liver, 12(2), pp.119~124 (2018), 거트앤리버 소화기연관학회협의회
- Asada K, "Demonstration of the usefulness of epigenetic cancer risk prediction by a multicentre prospective cohort study", Gut, 64, pp.388~396 (2015)
- Seiichiro Abe, "Metachronous Gastric Cancer Following Curative Endoscopic Resection of Early Gastric Cancer", Clinical Endoscopy, 51(3), pp.253~259 (2018), 대한소화기내시경학회
- Abe S, "Long-term surveillance and treatment outcomes of metachronous gastric cancer occurring after curative endoscopic submucosal dissection", Endoscopy, 47, pp.1113~1118 (2015)
- Park JY, "Risk factors for early metachronous tumor development after endoscopic resection for early gastric cancer", PLoS One, 12, pp.e0185501~ (2017)
- Yoon H, "Risk factors of residual or recurrent tumor in patients with a tumor-positive resection margin after endoscopic resection of early gastric cancer", Surg Endosc, 27, pp.1561~1568 (2013)
- Han JS, "A study of metachronous cancer after endoscopic resection of early gastric cancer", Scand J Gastroenterol, 46, pp.1099~1104 (2011)
- Hyun Jik Lee, "Characteristics of Synchronous and Metachronous Multiple Gastric Tumors after Endoscopic Submucosal Dissection of Early Gastric Neoplasm", Clinical Endoscopy, 51(3), pp.266~273 (2018), 대한소화기내시경학회
- Choi J, "Lymph node metastasis in multiple synchronous early gastric cancer", Gastrointest Endosc, 74, pp.276~284 (2011)
- Yasui W, "Molecular-pathological prognostic factors of gastric cancer : a review", Gastric Cancer, 8, pp.86~94 (2005)
- Choi SW, "Prognostic implications of microsatellite genotypes in gastric carcinoma", Int J Cancer, 89, pp.378~383 (2000)
- Wirtz HC, "Prognostic value and clinicopathological profile of microsatellite instability in gastric cancer", Clin Cancer Res, 4, pp.1749~1754 (1998)
- Calle EE, "Overweight, obesity and cancer : epidemiological evidence and proposed mechanisms", Nat Rev Cancer, 4, pp.579~591 (2004)
- Kim HJ, "Relationship between body mass index and the risk of early gastric cancer and dysplasia regardless of Helicobacter pylori infection", Gastric Cancer, 18, pp.762~773 (2015)
- Levi Z, "Body mass index at adolescence and risk of noncardia gastric cancer in a cohort of 1.79 million men and women", Cancer, 124, pp.356~363 (2018)
- Choi IJ, "Helicobacter pylori therapy for the prevention of metachronous gastric cancer", N Engl J Med, 378, pp.1085~1095 (2018)
- Choi JM, "Effects of Helicobacter pylori eradication for metachronous gastric cancer prevention : a randomized controlled trial", Gastrointest Endosc, 88, pp.475~485 (2018)
- Díaz P, "Helicobacter pylori and gastric cancer : adaptive cellular mechanisms involved in disease progression", Front Microbiol, 9, pp.5~ (2018)
- Yang Y, "Involvement of microRNAs-MMPs-E-cadherin in the migration and invasion of gastric cancer cells infected with Helicobacter pylori", Exp Cell Res, 367, pp.196~204 (2018)
- Yang HJ, "Helicobacter pylori-induced modulation of the promoter methylation of Wnt antagonist genes in gastric carcinogenesis", Gastric Cancer, 21, pp.237~248 (2018)
- Joo Hyun Lim, "Helicobacter pylori Is Associated with miR-133a Expression through Promoter Methylation in Gastric Carcinogenesis", Gut and Liver, 12(1), pp.58~66 (2018), 거트앤리버 소화기연관학회협의회
- Maeda M, "Novel epigenetic markers for gastric cancer risk stratification in individuals after Helicobacter pylori eradication", Gastric Cancer, 21, pp.745~755 (2018)
- Nakajima T, "Persistence of a component of DNA methylation in gastric mucosae after Helicobacter pylori eradication", J Gastroenterol, 45, pp.37~44 (2010)
- Xiao S, "Helicobacter pylori status and risks of metachronous recurrence after endoscopic resection of early gastric cancer : a systematic review and meta-analysis", J Gastroenterol, 54, pp.226~237 (2019)
- Conteduca V, "H. pylori infection and gastric cancer : state of the art(review)", Int J Oncol, 42, pp.5~18 (2013)
- Strong VE, "Progress in gastric cancer", Updates Surg, 70, pp.157~159 (2018)
- Cristescu R, "Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes", Nat Med, 21, pp.449~456 (2015)
- Kwon CH, "Gastric poorly cohesive carcinoma : a correlative study of mutational signatures and prognostic significance based on histopathological subtypes", Histopathology, 72, pp.556~568 (2018)
- De Franco L, "Prognostic value of perineural invasion in resected gastric cancer patients according to Lauren histotype", Pathol Oncol Res, 24, pp.393~400 (2018)